Mucosal *Escherichia coli* Bactericidal Activity and Immune Mediators Are Associated With HIV-1 Seroconversion in Women Participating in the HPTN 035 Trial

Charlene S. Dezzetti,1 Barbora A. Richardson,2,3 Jeanne M. Marmoza,4 Jessica Tegtmans,5 Gita Ramjoo,6 Taha Taha,7 Zezulera M. Chirowa,8 Salim S. Abdool Karim,9 Shannon L. Hillier,10 and Betsy C. Hesketh11 on behalf of the MTN Biomedical Sciences Working Group and the HPTN 035 Protocol Team

1Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, Mage-Women’s Research Institute, Pennsylvania; 2Department of Global Health, University of Washington, Seattle; Fred Hutchinson Cancer Research Center, Seattle, Washington; 3Department of Medicine, University of Washington, Seattle; 4Department of Medicine, Albert Einstein College of Medicine of Yeshiva University, New York, New York; 5Centre for Epidemiological Research in South Africa, Medical Research Council, Durban; 6Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; 7Department of Obstetrics and Gynecology, University of Zimbabwe, Harare, Zimbabwe; 8Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, and 9,10Departments of Pediatrics and Microbiology-Immunology, Albert Einstein College of Medicine of Yeshiva University, New York, New York.

The mucosal environment may impact the risk for human immunodeficiency virus type 1 (HIV-1) acquisition. Immune mediators were measured in vaginal fluid collected from HPTN 035 participants who acquired HIV-1 and from those who remained HIV-1 negative (controls). Mediator concentrations were similar in samples obtained before as compared to after HIV-1 acquisition in the 8 seroconverters. Compared with controls, seroconverters were more likely to have detectable levels of HBD-2 (odds ratio [OR], 2.39; *P* = .005) and greater *Escherichia coli* bactericidal activity (OR, 1.22; *P* = .01) prior to seroconversion. *E. coli* bactericidal activity remained significant in a multivariable analysis (*P* = .02) and may be a biomarker for HIV-1 acquisition.

Clinical trials evaluating the effectiveness of topical and oral preexposure prophylaxis (PrEP) to prevent female genital tract following cotus (eg, BufferGel) or polyunsaturated polymers that block HIV from binding to